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EPIDEMIOLOGY
Sentinel Case of Candida auris in the Western United States
Following Prolonged Occult Colonization in a Returned
Traveler from India
Michael H. Woodworth,1,* David Dynerman,2,* Emily D. Crawford,2 Sarah B. Doernberg,3
Lynn Ramirez-Avila,4 Paula Hayakawa Serpa,2,3 Amy Nichols,5 Lucy M. Li,2 Amy Lyden,2
Cristina M. Tato,2 Steve Miller,6 Joseph L. Derisi,2,7 and Charles Langelier2,3
Candida auris is an emerging multidrug-resistant yeast with high mortality. We report the sentinel C. auris case
on the United States West Coast in a patient who relocated from India. We identified close phylogenetic
relatedness to the South Asia clade and ERG11 Y132F and FKS1 S639Y mutations potentially explaining
antifungal resistance.
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Introduction
Candida auris is an emerging fungal pathogen withhigh minimum inhibitory concentrations (MICs) for many
antifungals. Since identification in 2009, it is increasingly
recognized as an important cause of invasive disease and
nosocomial outbreaks, with high-associated in-hospital
mortality of 40–72%.1 Genomic evaluation of strains
from multiple geographic regions suggests simultaneous
emergence of distinct geographic clades on three conti-
nents, as opposed to dissemination from a single source.1
This observation suggests that environmental factors
such as increased antifungal use may have contributed to
C. auris emergence.1
In addition to high fluconazole MICs, C. auris isolates
also frequently have high MICs for other antifungals, in-
cluding amphotericin and less frequently echinocandins.1
Despite the alarming frequency of elevated antifungal MICs
in C. auris, the underlying mechanisms and alleles associ-
ated with this resistance have not been fully characterized.
In C. auris as well as in other Candida species, mutations in
ERG11 (ergosterol synthetase), FKS1 (1,3 beta-d-glucan
synthetase), and FUR1 (uracil phosphoribosyltransferase)
have been associated with resistance to fluconazole, echi-
nocandins, and flucytosine, respectively.1,2 Previous studies
suggest that mutations in these genes can arise in the setting
of systemic antifungal therapy.3
Despite first appearing in the eastern United States in
2013, C. auris had not been detected on the United States
West Coast.2 In this study, we report the identification of
C. auris in this region, which was unusual in that it did not
establish endemicity, and use whole-genome sequencing
(WGS) to identify strain origin and evaluate genetic mecha-
nisms of antifungal resistance.
Methods
Case description
An elderly man with metastatic rectal cancer relocated
from India to California. He had received chemother-
apy and radiation while in India and had so undergone
intraabdominal surgeries complicated by sepsis. In the year
following his move, he required multiple admissions to the
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Center for management of his malignancy and for secondary
infections with carbapenem-resistant Enterobacteriaceae
(CRE), for which he was placed in contact isolation. During
his initial multi-month admission, two cultures from his ur-
ostomy grew 10,000 colony-forming units of a non-Candida
albicans yeast that was not further speciated due to unclear
clinical significance. In the course of his care, he was treated
with echinocandins with prophylactic intent. Several months
after initial admission, he was transitioned to palliative care.
Three days before death, a nephrostomy culture returned pos-
itive for yeast, which was ultimately speciated as C. auris.
Clinical microbiology and antifungal
susceptibility testing
Urine collected from the patient’s nephrostomy tube into
a sterile container underwent quantitative culture for bac-
teria and yeast using standard culture methods. Species
identification was made using matrix-assisted laser desorp-
tion ionization-time of flight mass spectrometry (Brucker
Diagnostics), which returned a score value of 2.14, and was
additionally confirmed by the California Department of
Public Health. Antifungal susceptibility testing was per-
formed using Sensititre YeastOne MIC plates (Trek Diag-
nostic Systems, Inc.), which has >95% agreement with the
Clinical Laboratory Standards Institute reference method.4
Whole-genome sequencing
DNA was extracted from the cultured C. auris isolate using
the Zymo ZR Bacterial/Fungal DNA kit. Library preparation
was completed with the New England Biolabs NEBNext
Ultra II DNA library prep kit and WGS was performed using
an Illumina NextSeq. The same DNA also underwent library
prep using the Oxford Nanopore Rapid Low Input by PCR
Barcoding Kit and WGS on a MinION instrument.
Genome assembly, phylogenetic analyses,
and antifungal resistance gene analysis
Raw Illumina sequencing reads were quality filtered using
PriceSeqFilter5 and then parsed with Nanopore reads for hybrid
de novo assembly using DBG2OLC.6 Reference-based whole-
genome phylogenetic analysis constructed from core genome
single-nucleotide polymorphisms (SNPs) was carried out with
the Northern Arizona SNP Pipeline7 using Pakistan strain
B8441 as the reference genome and incorporating genomes
from Lockhart et al.1 as well as C. auris isolate 16B15b con-
taining the FKS1 S639P mutation identified by Rhodes et al.3
RAxML-ng8 was used to build maximum likelihood phylo-
genetic trees as detailed in Supplementary Methods (see Sup-
plementary Tables S2–S4). To identify genetic mutations
associated with fluconazole or echinocandin resistance, Illu-
mina sequences were aligned against ERG11 (GenBank
KY410388.1) and FKS1 (GenBank XM_018312471.1) using
BowTie2.9 Mutations were confirmed by ERG11 and FKS1
PCR followed by Sanger Sequencing (Supplementary
Table S1) following previously described methods.10
Results
Assembly and phylogenetic characteristics
De novo hybrid assembly of Illumina and Oxford Nano-
pore reads produced a total of 33 contigs spanning 12 Mb,
characterized by 44.9% GC content, consistent with prior
estimates.1,3 Whole-genome phylogenetic analysis based on
a core genome of 208,384 SNPs placed this isolate within
the South Asia clade (Fig. 1A). On average, 56 SNPs sep-
arated this isolate from others from the South Asia clade
(Fig. 1B).
Phenotypic and genotypic assessment
of antifungal resistance
The California isolate demonstrated low MICs to am-
photericin (1 mg/mL), flucytosine (0.5 mg/mL), and vor-
iconazole (0.032 mg/mL). The isolate had an elevated
fluconazole MIC of 32 mg/mL. Assessment of this isolate’s
ERG11 (encoding ergosterol synthetase) allele revealed the
well-characterized Y132F substitution in the azole resis-
tance hotspot region.1,3 Unlike most C. auris strains, this
California isolate also exhibited a high caspofungin MIC of
8 mg/mL. Interrogation of FKS1 [encoding (1,3)-b-d-glucan
synthetase] revealed a S639Y mutation in the echinocandin
resistance hotspot 1 region (Supplementary Table S1).3,10
Discussion
C. auris emerges on the West Coast
of the United States
In this study, we report the first case of C. auris on the
United States West Coast, a region that had no previous
reports of the pathogen despite emergence in New York in
2013. The patient’s history of health care exposure in India
combined with the clustering of his C. auris isolate with the
South Asia clade by WGS phylogenetic analysis suggests
that he acquired C. auris abroad before hospitalization in
California. This finding supports current guidance from the
United States Centers for Disease Control and Prevention
to speciate all Candida in high-risk patients, including
those from regions of high C. auris prevalence, to allow for
early implementation of infection control measures.1,11
Following identification of C. auris, enhanced infection
control measures were implemented at UCSF, including
surface disinfection, a unit-level point prevalence survey,
and prospective surveillance. No additional cases of C. auris
at our medical center have been identified in over a year. This
case represents an unusual interruption in spread and prolonged
health care environmental contamination that has been char-
acteristic of detection of health care-associated C. auris. Early
implementation of contact precautions for CRE may have
contributed to curbing transmission of C. auris in this case.
This isolate had a high fluconazole MIC with an observed
ERG11 Y132F mutation.1,3 The California C. auris isolate
also demonstrated a high echinocandin MIC, which is ob-
served in <10% of C. auris strains.1 It is possible that this
patient’s prophylactic treatment with echinocandins could
have selected for resistance as observed in this isolate. This
C. auris isolate also had a FKS1 hotspot-1 region mutation,
which has been associated with echinocandin resistance in
multiple other Candida species.3,10 The identified FKS1
S639 substitutions of nonpolar residues (Y, F, P) has also
been identified in other C. auris strains with high echino-
candin MIC values, suggesting a key role for this amino acid
in echinocandin resistance.3,10
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FIG. 1. (A) Phylogenetic assessment based on core genome single-nucleotide polymorphisms demonstrated the four
known geographic clades1 and placed the California isolate within the South Asia clade. (B) Detailed phylogenetic tree
describing the South Asia clade, including the California isolate and United Kingdom outbreak isolate16B15b,3 which both
harbored the FKS1 S639P mutation. Color images are available online.
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Further study is needed to estimate the prevalence and
duration of colonization by this emerging pathogen. Future
work using WGS is needed to clarify the origins of C. auris,
transmission patterns, and mechanisms of resistance to
prevent and manage this emerging fungal pathogen of global
significance.
Data Availability
Raw sequences are available via BioProject ID
PRJNA480539.
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